82 related articles for article (PubMed ID: 2253231)
1. DNA in situ sensitivity to denaturation in bladder cancer and its correlation with tumor stage.
Bretton PR; Darzynkiewicz Z; Henry E; Kimmel M; Fair WR; Melamed MR
Cancer Res; 1990 Dec; 50(24):7912-4. PubMed ID: 2253231
[TBL] [Abstract][Full Text] [Related]
2. DNA in situ sensitivity to denaturation as a marker of human breast tumors.
Kunicka JE; Olszewski W; Rosen PP; Kimmel M; Melamed MR; Darzynkiewicz Z
Cancer Res; 1989 Nov; 49(22):6347-51. PubMed ID: 2804980
[TBL] [Abstract][Full Text] [Related]
3. DNA in situ sensitivity to denaturation: a new parameter for flow cytometry of normal human colonic epithelium and colon carcinoma.
Kunicka JE; Darzynkiewicz Z; Melamed MR
Cancer Res; 1987 Aug; 47(15):3942-7. PubMed ID: 3607742
[TBL] [Abstract][Full Text] [Related]
4. Prognosis of transitional cell bladder carcinoma. With special reference to ABH blood group isoantigen expression and DNA analysis.
Malmström PU
Scand J Urol Nephrol Suppl; 1988; 112():1-55. PubMed ID: 3068792
[TBL] [Abstract][Full Text] [Related]
5. Denaturation and condensation of DNA in situ induced by acridine orange in relation to chromatin changes during growth and differentiation of Friend erythroleukemia cells.
Darzynkiewicz Z; Traganos F; Kapuscinski J; Melamed MR
Cytometry; 1985 May; 6(3):195-207. PubMed ID: 3858089
[TBL] [Abstract][Full Text] [Related]
6. Molecular alterations associated with bladder cancer initiation and progression.
Cordon-Cardo C
Scand J Urol Nephrol Suppl; 2008 Sep; (218):154-65. PubMed ID: 18815930
[TBL] [Abstract][Full Text] [Related]
7. [Study of the DNA content of 72 cases of bladder tumors using flow cytometry. Relation with anatomoclinical data].
Devonec M; Hijazi A; Muchada E; Bouvier R; Dubernard JM
J Urol (Paris); 1986; 92(4):223-30. PubMed ID: 3782829
[TBL] [Abstract][Full Text] [Related]
8. Molecular genetic methods in the diagnosis of invasive bladder cancer.
Krause FS; Feil G; Zumbrägel A; Bichler KH
Anticancer Res; 2000; 20(6D):5015-21. PubMed ID: 11326660
[TBL] [Abstract][Full Text] [Related]
9. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
Lebret T; Bohin D; Kassardjian Z; Herve JM; Molinie V; Barre P; Lugagne PM; Botto H
J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
[TBL] [Abstract][Full Text] [Related]
10. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma.
Raman JD; Sosa RE; Vaughan ED; Scherr DS
Urology; 2007 Feb; 69(2):251-4. PubMed ID: 17320658
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the telomeric repeat amplification protocol (TRAP) assay for telomerase as a diagnostic modality in recurrent bladder cancer.
Dalbagni G; Han W; Zhang ZF; Cordon-Cardo C; Saigo P; Fair WR; Herr H; Kim N; Moore MA
Clin Cancer Res; 1997 Sep; 3(9):1593-8. PubMed ID: 9815848
[TBL] [Abstract][Full Text] [Related]
12. Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder: association with tumor progression.
King ED; Matteson J; Jacobs SC; Kyprianou N
J Urol; 1996 Jan; 155(1):316-20. PubMed ID: 7490878
[TBL] [Abstract][Full Text] [Related]
13. The value of DNA cytometry in transitional cell carcinoma of the urinary bladder.
Nenning H; Rassler J; Minh DH; Stolzenburg JU
Gen Diagn Pathol; 1997 Dec; 143(4):231-6. PubMed ID: 9489956
[TBL] [Abstract][Full Text] [Related]
14. [Changes in the mechanical integration of transitional epithelial cells and in the immune status of patients with bladder tumors].
Bocharova OA; Serebriakova RV; Golubeva VA; Figurin KM; Bukharkin BV; Bodrova NB; Matveev BP; Baryshnikov AIu
Urol Nefrol (Mosk); 1994; (3):27-30. PubMed ID: 8079407
[TBL] [Abstract][Full Text] [Related]
15. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
16. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
[TBL] [Abstract][Full Text] [Related]
17. The relation between p53 overexpression and lymph node metastases in clinical stage t2 and t3a transitional cell bladder carcinoma.
Uygur MC; Yaman I; Kutluay L; Altuğ U; Erol D
J Exp Clin Cancer Res; 1999 Sep; 18(3):391-5. PubMed ID: 10606186
[TBL] [Abstract][Full Text] [Related]
18. Surgically treated transitional cell carcinomas of the bladder. The role of radical surgery.
Al-Ali MA; Kashmoula DM; Haddad LF
Saudi Med J; 2002 Jun; 23(6):695-9. PubMed ID: 12070550
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder.
Durkan GC; Nutt JE; Rajjayabun PH; Neal DE; Lunec J; Mellon JK
Clin Cancer Res; 2001 Nov; 7(11):3450-6. PubMed ID: 11705862
[TBL] [Abstract][Full Text] [Related]
20. Nucleic acid content and nuclear chromatin structure of human bladder cell culture lines as studied by flow cytofluorometry.
Melamed MR; Darzynkiewicz Z; Traganos F; Sharpless TK
Cancer Res; 1977 Apr; 37(4):1227-31. PubMed ID: 844047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
